文献速递前列腺癌

遗传性侵袭性前列腺癌风险人群的前列腺癌筛查(PATROL)研究

The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.
PubMed 文献 · BJU Int · 2026-06-09

PATROL是一项多中心前瞻性早期检测研究,针对携带前列腺癌风险基因胚系致病变异且年龄≥40岁、未诊断前列腺癌的个体。主要终点是确定预设年龄导向PSA阈值和前列腺影像(如多参数MRI)对活检临床显著前列腺癌的阳性预测值,并探索临床病理特征、患者报告结局及生物标志物。

要点

  • 携带BRCA2、HOXB13、ATM等胚系致病变异者需更积极筛查。
  • 预设年龄导向PSA阈值:<50岁>1.0 ng/mL,50-59岁>1.5 ng/mL,≥60岁>2.0 ng/mL时建议活检。
  • 基线MRI为可选,PSA超过方案阈值时推荐影像检查。

核心结论

  • PATROL研究旨在确定年龄导向PSA阈值和前列腺影像对gPV携带者活检临床显著前列腺癌的阳性预测值。

研究设计与样本

  • 多中心前瞻性早期检测研究,纳入年龄≥40岁、携带前列腺癌风险基因gPV、无前列腺癌病史且无其他活动性恶性肿瘤的个体。

关键数值与推荐

  • 活检阈值:年龄<50岁PSA>1.0 ng/mL;50-59岁PSA>1.5 ng/mL;≥60岁PSA>2.0 ng/mL。
  • 基线MRI为可选,PSA超过方案推荐阈值时推荐MRI。
  • 每年进行体格检查和PSA检测。

临床怎么用

  • 对携带前列腺癌风险基因gPV的个体,可按年龄导向PSA阈值启动前列腺活检评估。
  • PSA超过年龄对应阈值时推荐多参数MRI检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines-e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53. However, the optimal early detection strategy for gPV carriers, including use of age-adjusted PSA thresholds and prostate imaging may be refined. and as a means to investigate novel biomarkers. STUDY DESIGN: 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) is a multicentre, prospective early detection study for individuals at increased risk for PCa due to carrying a gPV in a PCa risk gene. ENDPOINTS: The primary endpoint is to determine the positive predictive value of pre-defined age-directed prostate-specific antigen (PSA) level thresholds and prostate-specific imaging, e.g., multiparametric magnetic resonance imaging (MRI) for clinically significant PCa on biopsy for individuals at risk of PCa due to a gPV. Exploratory endpoints include characterising clinicopathological characteristics of PCa and patient-reported outcomes. Biospecimens will be collected to evaluate emerging clinical and research biomarkers. PATIENTS AND METHODS: Key eligibility includes: individuals aged ≥40 years who carry a gPV in an eligible gene, who have no prior diagnosis of PCa, do not have another active malignancy, and provide informed consent. Study procedures include annual physical examination and PSA. Imaging with MRI is optional at baseline and recommended if the PSA level is above the protocol-recommended PSA level threshold. Participants will be offered prostate biopsy for any clinical concern, PSA level >1.0 ng/mL if aged <50 years; PSA level >1.5 ng/mL if aged 50-59 years; PSA level >2.0 ng/mL if aged ≥60 years. If PCa is diagnosed, clinical care is determined by the participant and treating physician. If opting for active surveillance, study procedures will be collected annually for 10 years or until definitive treatment. If definitive treatment, study procedures will be collected for an additional 1 year. Long-term clinical outcomes will be collected annually until the study closes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Cheng HH, Maxwell KN, Salari K, et al. The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study. BJU Int. 2026. PMID: 42265755. doi:10.1111/bju.70334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。